Revlimid

Active substance

lenalidomide

Holder

Celgene sprl

Status

Running

Indication

diffuse large B cell lymphoma in patients who already received at least two prior treatment lines

Public documents

Approbation

Information for the patient

Informed consent

Last update

11/01/2021

Last updated on 13/04/2021